verapamil has been researched along with Hodgkin Disease in 5 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Hodgkin Disease: A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dexverapamil was escalated eight dose levels, from 240 to 1,200 mg/m2/d." | 6.68 | Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. ( Bates, SE; Bryant, G; Fojo, A; Herdt, J; Jaffe, ES; Regis, J; Steinberg, SM; Wilson, WH; Wittes, RE; Zhan, Z, 1995) |
| "One of 42 newly diagnosed and untreated lymphoma patients (2%) and seven of 11 previously treated and drug-resistant patients (64%) had detectable levels of P-glycoprotein (P less than ." | 5.28 | P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. ( Dalton, WS; Grogan, TM; Miller, TP; Salmon, SE; Scheper, RJ; Spier, CM, 1991) |
| "Dexverapamil was escalated eight dose levels, from 240 to 1,200 mg/m2/d." | 2.68 | Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. ( Bates, SE; Bryant, G; Fojo, A; Herdt, J; Jaffe, ES; Regis, J; Steinberg, SM; Wilson, WH; Wittes, RE; Zhan, Z, 1995) |
| "Etoposide was given daily (150 mg m-2 day-1) for three doses (each over 1 h); the first dose was given 12 h into the verapamil infusion." | 2.68 | Continuous-infusion verapamil with etoposide in relapsed or resistant paediatric cancers. ( Cowie, FJ; Dick, G; Flanagan, RJ; Judson, I; McCarthy, PT; Phillips, M; Pinkerton, CR, 1995) |
| "One of 42 newly diagnosed and untreated lymphoma patients (2%) and seven of 11 previously treated and drug-resistant patients (64%) had detectable levels of P-glycoprotein (P less than ." | 1.28 | P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. ( Dalton, WS; Grogan, TM; Miller, TP; Salmon, SE; Scheper, RJ; Spier, CM, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 4 (80.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wilson, WH | 1 |
| Bates, SE | 1 |
| Fojo, A | 1 |
| Bryant, G | 1 |
| Zhan, Z | 1 |
| Regis, J | 1 |
| Wittes, RE | 1 |
| Jaffe, ES | 1 |
| Steinberg, SM | 1 |
| Herdt, J | 1 |
| Cowie, FJ | 1 |
| Pinkerton, CR | 1 |
| Phillips, M | 1 |
| Dick, G | 1 |
| Judson, I | 1 |
| McCarthy, PT | 1 |
| Flanagan, RJ | 1 |
| Miller, TP | 1 |
| Grogan, TM | 1 |
| Dalton, WS | 1 |
| Spier, CM | 1 |
| Scheper, RJ | 1 |
| Salmon, SE | 1 |
| Gisslinger, H | 1 |
| Pirker, R | 1 |
| Wallner, J | 1 |
| Watzke, H | 1 |
| Ludwig, H | 1 |
| Demicheli, R | 1 |
| Jirillo, A | 1 |
| Bonciarelli, G | 1 |
| Lonardi, F | 1 |
| Balli, M | 1 |
| Bandello, A | 1 |
2 trials available for verapamil and Hodgkin Disease
| Article | Year |
|---|---|
Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa | 1995 |
Continuous-infusion verapamil with etoposide in relapsed or resistant paediatric cancers.
Topics: Adolescent; Adult; Bone Neoplasms; Child; Child, Preschool; Drug Administration Schedule; Drug Resis | 1995 |
3 other studies available for verapamil and Hodgkin Disease
| Article | Year |
|---|---|
P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa | 1991 |
Effect of combination chemotherapy with verapamil.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Epirubicin; Hodg | 1990 |
4'epidoxorubicin plus verapamil in anthracycline--refractory cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance; Epir | 1989 |